Matters arising vegetative state, rather than on the shoulders of those wishing to continue such treatment.4 As pertinent case law continues to evolve in America, however, this presumption, and accompanying burden, may be in danger of disintegrating. In this vein, one commentator has, indeed, espoused the view that it should be presumed that patients in a persistent vegetative state would not want to be kept alive indefinitely; and families objecting to the discontinuation of treatment would have the burden of showing why treatment should be continued after a specified time sufficiently long to establish irreversibility with high certainty.4
At this time juncture, however, the divisive legal, bioethical, and social issues emanating from cases involving a persistent vegetative state remain far from resolved; and continue to be considered on a piecemeal, or case by case, basis. In several very recent cases involving "medical futility", including one involving Baby K5 and another involving Baby Ryan,6 American courts have upheld the right of family members to insist on continued treatment over the objections of hospitals and doctors embracing a futility argument. Incidentally, healthcare providers in America who object to providing medical services which they claim are futile run a grave risk of being publicly charged with hypocrisy, or at least gross inconsistency. This is because medical services in the United States traditionally have been regarded as being simply another economic commodity, and have been dispensed based on ability to pay, rather than medical need. To embrace a differing mentality affecting, for example, patients in a persistent vegetative state, would constitute an obvious, and striking, departure from the accustomed path.
British Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening
Aramideh et all recently reported the results of botulinum toxin type A (BTA) treatment in patients with isolated blepharospasm or a combination of blepharospasm and "involuntary levator palpebrae inhibition". They concluded that the addition of two injections into the pretarsal portion, lateral and medial, of the upper eyelid to two injections into the junction of the preseptal and orbital portion of the upper eyelid, and one injection into the lower eyelid improved the beneficial response from 81% to 95% and prolonged the mean duration of benefit from 8 5 weeks to 12-6 weeks.
Our long term experience with pretarsal injections seems to support their findings.2 We have used this approach in over 300 patients treated for blepharospasm in our movement disorders clinic since 1983 and have also obtained a successful response rate of 95%. More recently, we have conducted a "single blind", controlled study comparing the effects of injecting BTX (BOTOXT M, Allergan) in the medial and lateral segments of the preseptal versus pretarsal portion of the orbicularis oculi in 14 patients with blepharospasm.' The pretarsal portion of the right eyelid and the preseptal portion of the left eyelid were injected with the same dose of BTA found to be effective in relieving blepharospasm during previous treatments. The mean dose per eyelid was 10-7 (range 5-15) mouse units. There was no difference in response between the two sides (latency: 6-4 days, peak effect: 3-9, mean duration of maximum benefit: 13-5 weeks, mean duration of total benefit: 16-2 weeks). Although eight patients reported ptosis in the left eye (preseptal), none had complications in the right eye (pretarsal) during the follow up period (3-5 months). The ptosis lasted a mean of 31-9 (range 14-64) days.
These findings strongly support the conclusion that BTA injections into pretarsal eyelids are associated with higher efficacy and lower frequency of complications than injections into the preseptal or orbital eyelids. Four patients of Aramideh et all who initially failed to respond to preseptal-orbital injections, but later improved with pretarsal injection, were found by EMG to have "involuntary levator inhibition" in addition to blepharospasm. We have also found that pretarsal injections of BTA are very effective not only in patients with blepharospasm, but also in patients with apraxia of eyelid opening (eyelid freezing), particularly when the involuntary eye closure is associated with or "triggered" by blepharospasm.
In our opinion, pretarsal injections of BTA into the upper eyelid are sufficient to obtain optimum results in patients with blepharospasm and eyelid freezing. 
